Work

Beyond Trial and Error: A Mathematical Model Wrangles DLBCL Heterogeneity Toward Optimizing Combination Therapy

Year: 2025

Type: article

Abstract: In this issue of Blood Cancer Discovery, Pomeroy and Palmer present a new mathematical model, incorporating both inter- and intra-patient heterogeneity, to accurately predict outcomes for first-line combination therapies in diffuse large B-cell lymphoma. Their quantitative framework opens a range of possibilities for optimizing trial design and lymphoma therapy with potential to expedite clinical development. See related article by Pomeroy and Palmer, p. 254.

Source: Blood Cancer Discovery

DOI: 10.1158/2643-3230.bcd-25-0071

Authors: Jordan S. Goldstein, Nick A. Phillips, Ash A. Alizadeh

Institutions: Stanford Medicine, Stanford University

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W4409456416

FWCI:

Cites: 10

Cited by:

Related to: 10